Bloomberg the Company

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Follow Us

Industry Products

Businessweek Archives

Helping Stroke Patients' Brain Cells To Survive


Developments to Watch

HELPING STROKE PATIENTS' BRAIN CELLS TO SURVIVE

Minimizing brain damage after a stroke depends on preventing the death of brain cells. As cells die, they release a chemical called glutamate, which overexcites neighboring cells, causing them to degrade and release more glutamate, provoking an ever-widening circle of brain-cell death.

Several types of chemicals stop the ripple effect by binding to a group of receptors called the NMDA complex. But they can cause side effects such as delirium and aggressive behavior. In animal studies, however, one of these compounds called glystasins inhibited the death of brain cells without side effects. This May, CoSensys Inc. of Irvine, Calif., and Ciba-Geigy Ltd. signed a pact to develop the CoSensys glystasin compound Acea 1021. Trials to evaluate the drug's safety and side effects in stroke victims are scheduled to begin in six months.EDITED BY RUTH COXETER


The Aging of Abercrombie & Fitch
LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus